MerLion Pharma Private
MerLion Pharmaceuticals is a drug discovery and development company focused on the development of novel antibiotics to combat bacterial infections in humans and animals. Their main product, Xtoro™, is a US FDA- and Health Canada-approved drug containing finafloxacin for the treatment of ear infections. Finafloxacin is also being developed as a medical countermeasure against biothreat agents and is an important candidate for the treatment of urinary tract infections and other hospital indications. MerLion Pharmaceuticals is dedicated to addressing the pressing problem of antibiotic-resistant bacteria and is working on developing finafloxacin for the human health sector. Finafloxacin is a next-generation fluoroquinolone antibiotic with unique properties, making it one of the safest and fastest acting fluoroquinolones available.
